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A B S T R A C T
Objective: International data have reported prostate cancer as the most fre-
quent among men, and the third highest in mortality. A rise in incidence has 
been observed in the course of recent decades, probably influenced by ear-
ly detection, mainly in asymptomatic men, through regular screening with pros-
tate-specific antigen (PSA) testing. The purpose of this study was to contribute 
to information on trends in prostate cancer incidence and mortality using popula-
tion-based data. 
Methods: This was an exploratory ecological study of time trends, aiming at describing 
changes in prostate cancer incidence and mortality in Aracaju, Sergipe, Brazil, from 1996 
to 2006. Rates were calculated from data of the Registro de Câncer de Base Populacional de 
Aracaju. Trends were calculated using the Joinpoint Regression Program. 
Results: For the study period, 1,490 incident cases and 334 deaths were included. Incident 
cases were more common after 50 years of age, and deaths after 55 years. Age-standardized 
incidence rates of 46.6 and 50.0/100,000 were observed in the early years of the series, 
and then progressively increased, with rates higher than 100.0/100,000 in later years. For 
mortality, age-standardized rates varied from 21.6 and 16.6/100,000 to 24.1 and 28.9/100,000 
in later years. Joinpoint analysis identified one joinpoint for the incidence series, resulting 
in two trends, the first with annual percent change of 34% and the second with 5.8%; for 
the mortality series no joinpoint was identified, and the annual percent change was 2.1%. 
Conclusion: There was a sharp increase in incidence rates during the study period, probably 
due to screening. Mortality rates had a small upward trend, and did not show major 
changes during the study period.
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Tendências temporais de incidência e mortalidade por câncer de próstata 
em uma cidade de médio porte do nordeste brasileiro
R E S U M O
Objetivo: Dados internacionais apontaram o câncer de próstata como o mais incidente e o 
terceiro em mortalidade entre os homens. O aumento da incidência tem sido observado nas 
últimas décadas, provavelmente por causa da detecção precoce, principalmente em homens 
assintomáticos, através do rastreamento regular com dosagem do antígeno prostático 
específico (PSA). O objetivo do estudo foi contribuir com as informações sobre as tendências 
de incidência e mortalidade por câncer de próstata a partir de extratos populacionais. 
Métodos: Tratou-se de um estudo ecológico exploratório de tendências temporais, visando 
descrever as mudanças de incidência e mortalidade por câncer de próstata em Aracaju, SE, 
Brasil, no período de 1996 a 2006. As taxas foram calculadas a partir dos dados do Registro 
de Câncer de Base Populacional de Aracaju e as tendências temporais foram determinadas 
pelo Joinpoint Regression Program. 
Resultados: No período do estudo, 1490 casos incidentes e 334 mortes foram incluídos. Os 
casos incidentes foram mais frequentes a partir de 50 anos de idade e as mortes a partir 
de 55 anos. Taxas padronizadas de incidência de 46,6 e 50,0/100.000 foram observadas nos 
primeiros anos da série, e um aumento progressivo acima de 100,0/100.000 foi observado 
nos últimos anos. Para a mortalidade, as taxas padronizadas variaram de 21,6 e 16,6/100.000 
para 24,1 e 28,9/100.000. A análise do Joinpoint identificou duas tendências para a incidência, 
a primeira com percentual de mudança de 34,0% e a segunda com percentual de 5,8%; para 
a mortalidade, a análise resultou em uma tendência com percentual de 2,1%. 
Conclusão: Houve um grande aumento nas taxas de incidência, provavelmente devida ao 
rastreamento, durante o período de estudo. A mortalidade, entretanto, mesmo com uma 
pequena tendência de aumento, não apresentou grandes mudanças no tempo estudado.
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Introduction
International data have reported prostate cancer as the most 
frequent among men, and the third highest in mortality.1 In 
Brazil, prostate cancer has been the most incident cancer and 
the second most common cause of cancer-related death in 
men.2,3 A rise in incidence has been observed in the course of 
recent decades, probably influenced by early detection, mainly 
in asymptomatic men. Published data in Europe have shown 
an increase in prostate cancer incidence since the 1990s, 
with figures higher than 7% yearly.4 Despite this increase in 
incidence being related to early detection, a negative impact 
in mortality rates has not been consistent.4,5
Prostate cancer risk has increased with age, due to 
individual factors and diminished antitumor mechanisms, 
and has rarely been diagnosed under the age of 50. Prostate 
cancer five-year survival rates have been rising in high income 
countries, surpassing 70%, while in low income countries it 
has usually been below 50%.6
The aim of screening has been to identify men in the 
general population who have had no suspicion of prostate 
cancer; however, this approach has been controversial 
because prostate cancer mortality rates have remained stable, 
and have not shown differences between screened and non-
screened groups. Another feature of this disease has been 
that it has often followed an indolent form that would not 
progress to aggressive forms if left untreated. Others, on the 
contrary, have stated that there should be a subset of lethal 
disease and, for that subset, screening could provide a chance 
for cure.1,4,5
In the 1990s, the concept of screening adult men for 
prostate-specific antigen (PSA) was introduced, aiming at 
decreasing morbidity and mortality caused by advanced 
disease. Since then, increased incidence has been observed and 
asymptomatic tumors have been detected.4 As to the mortality 
rates, some studies have not shown significant changes after 
the advent of PSA testing,4,6 while others have.7,8
In Brazil, screening has not been conducted systematically, 
and PSA testing has been applied opportunistically, usually 
at the suggestion of the patient or his physician; however, 
there has been growing awareness that screening should be 
performed.
Current evidence has been questioning the routine use of 
screening for prostate cancer with PSA testing.9 Due to its 
growing incidence, this cancer has inflicted a great burden 
on society, especially with population aging.
The purpose of this study has been to contribute with 
information on trends in prostate cancer incidence and 
mortality using population-based data from 1996 to 2006 
in the municipality of Aracaju, capital of the Northeastern 
Brazilian state of Sergipe, and to provide means to implement 
control strategies for this common cancer.
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
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Methods 
This was an exploratory ecological study of time trends, 
aimed at describing changes in prostate cancer incidence 
and mortality in Aracaju, Sergipe, Brazil. Incidence data were 
obtained from the database of the Registro de Câncer de Base 
Populacional de Aracaju (Cancer Registry). The Cancer Registry 
actively collected cancer cases from public and private 
sources such as hospitals, diagnostic and treatment clinics, 
pathology laboratories, units that provide comprehensive 
cancer treatment, and from governmental databases such as: 
the mortality system, the systems of information on hospital 
and outpatient procedures, and the system of information 
on breast and cervical cancer. The Cancer Registry followed 
the rules organized by the International Agency for Research 
on Cancer (IARC) as defined by the Brazilian National 
Cancer Institute (Instituto Nacional do Câncer – INCA). All 
cases of invasive prostate cancer diagnosed in the years of 
reference were included for analysis. The means of diagnosis 
considered were: histology, cytology, imaging, clinical and 
laboratory evidence, and surgical findings. Duplicity of cases 
was managed by Cancer Registry software, which verified 
available information in the several sources and databases. 
Classification and coding were performed according to 
the International Classification of Diseases for Oncology, 
2nd edition (ICDO-2) until 2004, and the 3rd edition (ICD-3) 
from 2005 on. For publication reference, the International 
Classification of Diseases, 10th edition (ICD-10) was used. 
For mortality, the ICD-10 was also used. The topography 
considered was C61. The database prepared for analysis 
contained all invasive cancer cases, except non-melanoma 
skin cancer. Mortality data were retrieved from the Mortality 
Database of the State of Sergipe, which provided information 
for the National Mortality Database. The Cancer Registry, as 
a branch of the State Health Agency, had full access to the 
mortality database, including the digitalized death certificates. 
All invasive prostate cancer cases and all prostate cancer 
deaths identified from 1996 to 2006 were included for analysis. 
Crude rates (CR) and age-standardized rates (ASR), adjusted by 
the world population,10,11 were calculated using the official 
software of the Cancer Registry.12 Trends in incidence and 
mortality were calculated using the Joinpoint Regression 
Program,13 version 3.5.2, which was developed for non-
commercial use by the National Cancer Institute, USA. This 
software has been broadly used to estimate future trends of 
time series based on the calculation of the annual percent 
change (APC). This program assumed the model based on a 
minimal number of joinpoints where statistically significant 
changes in time trends would occur, enabling to test whether 
an apparent change in trend would be statistically significant. 
A logarithmic linear regression model added join points 
from 0 to 5, and calculated the difference up to a statistically 
significant value, using the Monte Carlo permutation test.14 
Thus, the APC was calculated to define time trends in prostate 
cancer incidence and mortality. A significant increase of a 
trend was defined as the slope of the curve being statistically 
significant (p < 0.05).
Results
From 1996 to 2006, 1,490 cases of invasive prostate cancer were 
identified by the Cancer Registry of Aracaju, and 334 deaths 
were retrieved from the mortality database for analysis. 
Table 1 shows the incidence and mortality data of the 
time series. Age-standardized incidence rates of 46.6 and 
50.0/100,000 were observed in the early years; incidence 
progressively increased over the subsequent years, with 
rates higher than 100.0/100,000. Age-standardized mortality 
 Table 1 – Prostate cancer incidence, mortality, and mortality-to-incidence ratio in Aracaju, Sergipe, Brazil, for the period 
of 1996 to 2006.
Incidence Mortality M:I
Year n Crude rate ASR n Crude rate ASR
1996 52 26.0 46.6 23 11.5 21.6 0.44
1997 53 26.1 50.0 18 8.9 16.3 0.34
1998 88 42.7 79.3 23 11.2 20.7 0.26
1999 124 59.5 113.5 33 15.8 28.0 0.27
2000 139 64.4 114.8 35 16.2 26.2 0.25
2001 126 57.5 97.7 31 14.2 23.3 0.25
2002 148 66.8 113.6 35 15.8 24.8 0.24
2003 155 69.1 117.9 27 12.0 18.0 0.17
2004 191 84.1 139.8 32 14.1 23.6 0.17
2005 223 95.6 165.2 35 15.0 24.1 0.16
2006 191 80.8 145.1 42 17.8 28.9 0.22
Total 1,490 – – 334 – – –
Average – 61.0 107.6 – 13.8 23.2 –
ASR, age-standardized rate (world population); M:I, mortality-to-incidence ratio.
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rates showed variation from 21.6 and 16.6/100,000 to 24.1 and 
28.9/100,000 in the later years of the series. The mortality-to-
incidence ratio, which expresses the risk of dying of prostate 
cancer, had a mean value of 0.25. 
Age-standardized incidence and mortality rates increased 
with age. Higher incidence rates were observed for the 
following age groups: 50 to 54 years = 70.5/100,000; 55 to 59 
years = 195.0/100,000; 60 to 64 years = 376.2/100,000; 65 to 
69 years = 786.0/100,000; 70 to 74 years = 1112.6/100,000; 75 to 
79 years = 1462.6/100,000; 80 to 84 years = 1901.0/100,000; and 
85 years and above = 1935.7/100,000. Higher mortality rates 
were identified for the following age groups: 55 to 59 years = 
23.3/100,000; 60 to 64 years = 42.9/100,000; 65 to 69 years = 
94.6/100,000; 70 to 74 years = 187.6/100,000; 75 to 79 years = 
473.4/100,000; 80 to 84 years = 655.3/100,000; and 85 years and 
above = 1042.1/100,000.
Joinpoint analysis identified one joinpoint for the incidence 
series, separating two trends: 1996 to 1999, and 1999 to 2006 
(Table 2). For incidence, the 1996 to 1999 trend had a sharp 
significant increase with an APC of 34%; the 1999 to 2006 trend 
showed a less steep slope (Fig. 1), still with a significant APC of 
5.8%, which was equal to the average annual percent change 
(AAPC) of the last five years the series, the latter correlating 
better with future trends. For the mortality series, the number 
of joinpoints was zero, and the whole series was considered 
as a single trend. The APC of the single trend and the AAPC of 
the last five years was 2.1% (the confidence interval included 
0, thus not being significantly different from the 0 joinpoint 
at alpha = 0.05) (Table 2), showing a less steep slope of the 
mortality trend (Fig. 1). 
Discussion
Prostate cancer incidence has been showing increasing rates 
in Western countries but conversely lower rates in Asia;15 
however, there has been a trend of rising incidence rates 
globally, mainly because early tumors have been diagnosed 
more often.4,16 In Brazil, reports have shown incidence rates 
of 112.1/100,000 in Brasilia DF, 99.3/100,000 in Goiania, and 
86.4/100,000 in São Paulo.17 In the present study, ASIRs of 
46.6 and 50.0/100,000 in the early years of the series might 
reflect two points: first, that these were the beginning years 
of the Cancer Registry of Aracaju and case collection was 
not comprehensive; and second, that PSA testing was not 
systematically used at that time. Increasing ASIRs have 
been observed over time. Aracaju had a comparatively high 
incidence rate of prostate cancer with an average ASR of 
107.6/100,000, and even higher if the last eight years of the 
series are considered, with an average rate of 125.9/100,000.
Incidence time trends presented APC of 34.0% for the 1996 to 
1999 period and then a less steep pattern of ascension with APC 
of 5.8%. International data have shown that future estimates 
can be more precisely performed using data from the most 
recent years. The AAPC based on the five last observations 
also showed an increasing tendency of 5.8%. This pattern 
of ascension is remarkable compared to international data, 
despite the great variance of the reported data.15,18,19
The trend of diagnosing prostate cancer in earlier stages 
has been observed worldwide; it has also been shown that 
the average age at diagnosis has decreased.20 The increasing 
incidence rates might be due to several diagnostic means 
resulting in discovering early tumors; however, in population-
Table 2 – Joinpoint analyses of prostate cancer incidence and mortality with the annual percent change (APC), the 
average annual percent change (AAPC) and 95% confidence interval (CI).
Trend 1 Trend 2 Last five years
Years APC CI Years APC CI AAPC CI
Incidence 1996-1999 34.0a 2.1-75.0 1999-2006 5.8a 0.8-11.1 5.8a 0.8-11.1
Mortality 1996-2006 2.1b  -1.3-5.7 _ _ _ 2.1b  -1.3-5.7
aThe APC and AAPC are significantly different from zero at alpha = 0.05; 
bThe APC and AAPC are not significantly different from zero at alpha = 0.05.
Fig. 1 – Joinpoint for prostate cancer incidence and 
mortality in Aracaju, Sergipe, Brazil, 1996-2006.  
ASR, age-standardized rate (world population).
160
150
140
130
120
110
100
90
80
70
60
50
28.00
27.00
26.00
25.00
24.00
23.00
22.00
21.00
20.00
19.00
18.00
17.00
 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Year
 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Year
All : 0 Joinpoints
All : 1 Joinpoint
A
S
R
A
S
R
 REV ASSOC MED BRAS. 2013; 59(1):15-20 19
based studies, staging has not been broadly referred.18 Despite 
the uncertainty about the impact of PSA testing over mortality, 
there has been no doubt about its effect on incidence.21 Some 
studies have not only reported advances in other diagnostic 
means such as echography and biopsy material, but also have 
demonstrated great development in medical and surgical 
therapy.2,18 
It cannot be said that the mortality rates have remained 
unchanged over the last decades; actually, there has been a 
slight decreasing tendency.18 The present study showed that 
age-standardized mortality rates had an increasing trend with 
APC of 2.1%, which is contrary to data observed in high-income 
countries,4,8,16 but still comparable with Brazilian reports.3 An 
average ASR of 23.2/100,000 was calculated, considering the 
whole series of 1996 to 2006. The mortality-to-incidence ratio 
of 0.25 is a good predictor of survival and is similar to data 
observed in high income countries.22
Another point to be discussed is the actual benefit derived 
from screening and subsequent treatment, since prostate 
cancer has been diagnosed predominantly in older men with 
comorbidities, as confirmed by the present data. In a study 
of PSA testing, it was estimated that 1,410 men needed to 
be screened and 48 treated in order to avoid one death.23 
Conversely, other studies have stated that in countries where 
screening was systematic there has been remarkable decreases 
in mortality rates.8,24 This should be taken into account since 
prostate cancer often shows favorable outcomes.
PSA screening for prostate cancer has been a matter of 
discussion worldwide. Evidence has been provided that 
screening may lead to over-diagnosis and consequently to over-
treatment of indolent disease. Current means of diagnosis and 
treatment could lead to undesirable morbidity and mortality. 
Since the benefit of the test has been controversial, especially 
in older men, most guidelines have not supported population 
screening; however, testing should be available upon physician 
and patient request. Early diagnosis of high-risk tumors might 
lead to more effective treatments and improved survival, but it 
has not been easy to select those patients needing treatment 
from those who could be observed. Mortality rates have 
declined in high-income countries since the initiation of PSA 
screening, but it has been debated whether this was the actual 
reason and alternative factors have been proposed, such as the 
use of hormonal treatment for asymptomatic bulky disease.25 
There has been growing evidence that screening has little 
impact on mortality, and effort should be made to identify 
high-risk patients that could benefit from early diagnosis and 
treatment.
Limitations 
The Cancer Registry of Aracaju has collected cancer cases for 
the whole state of Sergipe to select the cases from the capital, 
Aracaju. This practice, although comprehensive for case 
identification, has resulted in delay to close the annual data 
base, and case ascertainment has been more tedious. Since 
several sources of information have been used, cases could be 
found in more than one source, and thus, extra care has been 
exercised to avoid duplication. There has been a number of 
cases where place of residency could not be determined; after 
consulting all sources and databases, a few cases still had to be 
excluded. Mortality rates have been calculated from the official 
State Mortality Database; cause of death has been called into 
question and could jeopardize conclusions.
Conclusion 
Worldwide prostate cancer incidence rates have increased 
sharply, as also observed in the present study, probably 
due to a screening effect. For mortality rates, differently 
from international data, a slight increasing trend has been 
observed. This study did not aim to analyze the causes of the 
increase in incidence rates and the impact on mortality rates; 
more research needs to be conducted to determine which 
patients might benefit from screening and treatment without 
unnecessary interventions, and to better design strategies to 
reduce prostate cancer mortality. 
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